Research Article

Cardiac Rehabilitation Increases SIRT1 Activity and β-Hydroxybutyrate Levels and Decreases Oxidative Stress in Patients with HF with Preserved Ejection Fraction

Graziamaria Corbi, Valeria Conti, Jacopo Troisi, Angelo Colucci, Valentina Manzo, Paola Di Pietro, Maria Consiglia Calabrese, Albino Carrizzo, Carmine Vecchione, Nicola Ferrara, and Amelia Filippelli

1Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
2Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy
3Theoreo srl, Via degli Ulivi 3 84090 Montecorvino Pugliano, Italy
4European Biomedical Research Institute of Salerno (EBRIS), Via S. de Renzi 3, 84125 Salerno, Italy
5IRCCS Neuromed, Department of Vascular Physiopathology, Pozzilli, Italy
6Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy
7Istituti CliniciScientificiMaugeriSpASocietàBenefit(ICS Maugeri Spa SB), TeleseTerme, Italy

Correspondence should be addressed to Valeria Conti; vconti@unisa.it

Received 31 May 2019; Revised 14 September 2019; Accepted 22 October 2019; Published 27 November 2019

Academic Editor: Massimo Collino

Copyright © 2019 Graziamaria Corbi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Exercise training induces beneficial effects also by increasing levels of Sirtuin 1 (Sirt1) and β-hydroxybutyrate (βOHB). Up to date, no studies investigated the role of exercise training–based cardiac rehabilitation (ET-CR) programs on βOHB levels. Therefore, the present study is aimed at investigating whether a supervised 4-week ET-CR program was able to induce changes in Sirt1 activity and βOHB levels and to evaluate the possible relationship between such parameters, in Heart Failure with preserved Ejection Fraction (HFpEF) patients.

Methods. A prospective longitudinal observational study was conducted on patients consecutively admitted to the Cardiology and Cardiac Rehabilitation Units of “San Gennaro dei Poveri” Hospital in Naples, Italy. In fifty elderly patients affected by HFpEF, in NYHA II and III class, Sirt1 activity, Trolox Equivalent Antioxidant Capacity (TEAC), βOHB, and Oxidized Low-Density Lipoprotein (Ox-LDL) levels were measured before and at the end of the ET-CR program. A control group of 20 HFpEF patients was also recruited, and the same parameters were evaluated 4 weeks after the beginning of the study. Results. ET-CR induced an increase of Sirt1 activity, βOHB levels, and antioxidant capacity. Moreover, it was associated with a rise in NAD+ and NAD+/NADH ratio levels and a reduction in Ox-LDL. No changes affected the controls.

Conclusion. The characterization of the ET-CR effects from a metabolic viewpoint might represent an important step to improve the HFpEF management.

1. Introduction

Despite recent advances in both pharmacological and non-pharmacological therapies, heart failure (HF) is still a prevalent cause of death or permanent invalidity worldwide [1]. The exercise training–based cardiac rehabilitation (ET-CR) surely represents a valid nonpharmacological therapeutic approach against HF; nevertheless, it is still underprescribed in aged patients. The reason for this behavior could be ascribed to their comorbidity and polytherapy that complicate the participation in the ET-CR programs.

In HF, tissue hypoxia, caused either by low cardiac output or by sympathetic vasoconstriction, may also trigger a significant increase in the production of free radicals [2]. In fact, oxidative stress, which occurs when reactive oxygen species (ROS) are produced in excess and overcome the action of...
the endogenous antioxidants mechanisms, is implicated in the pathophysiology of HF. This is proved by a correlation between oxidative stress markers and HF in human and animal studies [3, 4] and by direct molecular evidence about an etiological role of ROS [5] in cardiovascular diseases, including HF.

During life, the cardiovascular system is constantly exposed to oxidative stress; hence, the balance between the production of ROS and activation of the antioxidant defence system is crucial for the human physiology and control of the cellular homeostasis [6].

Several in vitro and in vivo studies have demonstrated that ROS activation might occur in HF as a response to various stressors [7]; animal studies have also suggested that antioxidants and ROS defence pathways can ameliorate ROS-mediated cardiac abnormalities [8].

Up to date, no effective therapies for reducing morbidity or mortality in HF with preserved ejection fraction (HFpEF) are available, limiting the treatment for symptom relief and comorbidity management in such a category of patients [9, 10]. A key barrier to therapeutic development is a significant lack of knowledge about HFpEF pathogenesis and pathophysiology [11, 12]. Thus, elucidating molecular mechanisms and identifying novel therapeutic targets in the HFpEF phenotype are essential needs to improve the management of these patients [13].

A recent meta-analysis demonstrated that ET-CR is associated with improvements in cardiorespiratory fitness and quality of life of the patients with HFpEF [14]. ET, as part of CR, is effective in inducing beneficial effects at cardiac level via the reduction of the oxidant amount and stimulation of the antioxidant capacity [15, 16].

An important mechanism, involved in the cellular response to exogenous stressors, is represented by the sirtuins, NAD+-dependent deacetylases, now recognized as oxidative stress sensors and modulators of cellular redox state [17, 18].

A supervised ET-CR program increases the activity of the best-characterized member of sirtuins, Sirt1. As a consequence, a systemic antioxidant defence in elderly HFpEF patients is stimulated by inducing the activation of Sirt1’s molecular targets, such as the antioxidants superoxide dismutases (SODs) and catalase [19]. Interestingly, Nagao et al. [20] have demonstrated that myocardial β-OHB has the potential to exert compensatory antioxidant effects under pathological conditions. In particular, the authors found that β-OHB was elevated in failing mouse hearts, attenuated ROS production, and alleviated apoptosis induced by oxidative stress, suggesting that a build-up of β-OHB might occur as a compensatory response against oxidative stress in failing hearts. Besides, ketone bodies have been proposed as agents mimicking the effects of caloric restriction which is considered a valid therapeutic approach linked to the beneficial effects of Sirt1 [21]. So far, no studies have been performed to investigate the role of an ET-CR program on β-OHB levels. Therefore, the main aims of the present study were to investigate whether a supervised 4-week ET-CR program was able to induce changes in Sirt1 activity and β-OHB levels and to evaluate the possible relationship between these two parameters in HFpEF patients.

2. Methods

2.1. Study Design and Population. A prospective longitudinal observational study was conducted in patients consecutively admitted to the Cardiology and Cardiac Rehabilitation Units of “San Gennaro dei Poveri” Hospital of Naples, Italy. Patients’ written informed consent forms were collected; the study was approved by the local Medical Research Ethics Committee and was performed in accordance with the Declaration of Helsinki Fifth Revision (2013) and its amendments. This report adheres to the standards for the reporting of observational trials and was written according to the STROBE guidelines for Observational Studies in Epidemiology-Molecular Epidemiology (STROBE-ME) [22].

Male elderly subjects with HF in clinically stable condition, classified as in NYHA II and III class and with a preserved ejection fraction (EF) (70 with HF preserved EF), were enrolled. All definitions were based on the ESC and ACCP/AHA criteria, in which the term “stable” defines treated patients with symptoms and signs remained generally unchanged for at least a month [23, 24].

Of the study population, 50 patients underwent a well-structured ET-CR program of 4 weeks, while 20 patients represented the control group. The reasons why the control group did not undergo ET-CR program were related to individual circumstances that have made unpractical the participation in an outpatient program (e.g., patients who lived in a long-term care facility or no cardiac rehabilitation program available within 60 minutes of travel time from the patient’s home).

The exclusion criteria included unstable angina pectoris, use of nitrates, uncompensated HF, complex ventricular arrhythmias, pacemaker implantation, and orthopedic or neurological limitations to exercise. No sex-based or racial/ethnic-based differences were present between the groups.

All enrolled patients underwent a physical examination, collection of demographic and routine blood chemistry tests, chest X-ray, blood pressure measurement, electrocardiographic and echocardiographic examinations, and a cardiopulmonary stress test at baseline.

After 4 weeks, both groups underwent physical examination and blood chemistry tests.

None of the patients had experienced a myocardial infarction in the 12 months preceding the study, and based on body mass index, none were cachectic (Table 1).

2.2. Training Protocol. Patients underwent a 4-week structured exercise training, on a hospital ambulatory-based regimen. At an initial stage, on a cycle ergometer, the progression of aerobic exercise training provided an intensity set at 50% VO2 max, based on the performance achieved in the cardiopulmonary stress test. The exercise duration was increased from 15 to 30 min, according to perceived symptoms and clinical status, for the first 1–2 weeks. A gradual increase of intensity (60–70% of peak VO2, if tolerated) was achieved within 2 weeks [25]. The target of 60–70% VO2 peak was...
then utilized to schedule each exercise session at the beginning of the 4-week training program. The exercise workload was gradually increased until the achievement of the predefined target. Each session was forerun by a 10 min unloaded warm-up phase and followed by a 5 min unloaded cool-down [26]. The training sessions were performed 5 times per week, under continuous electrocardiographic monitoring, and supervised by a cardiologist, a physiotherapist, and a graduate nurse.

2.3. Blood Sample Collection. Overnight fasting blood samples were obtained at baseline and after 4 weeks in both the groups. After centrifugation at 1500 × g for 10 min, plasma samples were transferred to new tubes and stored at −80°C until analysis. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll-Paque PLUS (GE Healthcare, Munich, Germany), according to the manufacturer’s procedures.

2.4. Sirt1 Activity. Sirt1 activity was determined, in nuclei extracted by PBMCs of all recruited subjects, using a SIRT1/Sir2 Deacetylase Fluorometric Assay (CycLex, Ina, Nagano, Japan) and 96 flat bottom transparent polystyrene plates (Thermo Fisher Scientific, USA), following the manufacturer’s instructions. Values were reported as relative fluorescence/μg of protein (AU). All data are expressed as the mean ± SD of three independent experiments. Replicated sample analysis showed a coefficient of variation (CV) < 5%.

2.5. β-Hydroxybutyrate Plasma Levels. β-Hydroxybutyrate (βOHB) extraction, purification, and derivatization were carried by the MetaboPrep GC kit (Theoreo, Montecorvino Pugliano, Italy). According to the protocol by Troisi et al. [27], 50 μL of sample was added to 200 μL of extraction mix solution containing the internal standard. The sample and extraction mixture were vortexing at 1250 rpm for 30 seconds. The extract was centrifuged for 5 minutes at 16000 rpm, keeping the temperature below 4°C. Two hundred microliters of the upper liquid phase was removed and transferred into a microcentrifuge tube containing the purification mixture (200 μL). This was vortexed at 1250 rpm for

| Variables                  | Total population | Ctr | ET-CR | \( p \) |
|---------------------------|------------------|-----|-------|--------|
| Age (years), mean ± SD    | 69.5 ± 4.3       | 70.25 ± 4.7 | 69.20 ± 4.1 | 0.357  |
| BMI (kg/m²), mean ± SD    | 27.6 ± 3.2       | 26.7 ± 3.3 | 27.9 ± 3.1 | 0.154  |
| SBP (mmHg), mean ± SD     | 120.9 ± 11.0     | 119.3 ± 11.0 | 121.5 ± 11.0 | 0.443  |
| DBP (mmHg), mean ± SD     | 71.7 ± 5.7       | 71.0 ± 5.3 | 72.0 ± 5.9 | 0.511  |
| EF (%), mean ± SD         | 56.7 ± 4.0       | 57.9 ± 3.8 | 56.2 ± 4.0 | 0.117  |
| LVEDD (mm)                | 52.27 ± 4.27     | 52.95 ± 4.19 | 52.00 ± 4.35 | 0.404  |
| CAD, n (%)                | 14 (71.4)        | 14 (70) | 36 (72) | 0.542  |
| PTCA, n (%)               | 37 (52.9)        | 11 (55) | 26 (52) | 0.516  |
| CABG, n (%)               | 10 (14.3)        | 3 (15) | 7 (14) | 0.59   |
| Previous IMA, n (%)       | 47 (67.1)        | 13 (65) | (68) | 0.51   |
| Valvular substitution, n (%) | 3 (4.3)    | 1 (5) | 2 (4) | 0.642  |
| Smoking, n (%)            | 37 (52.9)        | 9 (45) | 28 (56) | 0.285  |
| Hypertension, n (%)       | 30 (42.9)        | 8 (40) | 22 (44) | 0.487  |
| Dislipidemia, n (%)       | 31 (44.3)        | 9 (45) | 22 (44) | 0.574  |
| Diabetes, n (%)           | 14 (20)          | 4 (20) | 10 (20) | 0.619  |
| COPD, n (%)               | 13 (18.6)        | 4 (20) | 9 (18) | 0.545  |
| Beta blockers             | 64 (91.4)        | 18 (90) | 46 (92) | 0.556  |
| ACE inhibitors            | 32 (45.7)        | 9 (45) | 23 (46) | 0.576  |
| ARBs                      | 9 (12.9)         | 2 (10) | 7 (14) | 0.495  |
| Diuretics                 | 20 (28.6)        | 5 (25) | 15 (30) | 0.458  |
| Ca2 antagonists           | 7 (10)           | 2 (10) | 5 (10) | 0.652  |
| Aspirin                   | 56 (80)          | 15 (75) | 41 (82) | 0.361  |
| Anticoagulants            | 33 (47.1)        | 9 (45) | 24 (48) | 0.516  |
| Oral hypoglycemics        | 11 (15.7)        | 4 (20) | 7 (14) | 0.385  |
| Insulin                   | 5 (7.1)          | 1 (5) | 4 (8) | 0.556  |
| Statin                    | 53 (75.7)        | 15 (75) | 38 (76) | 0.578  |

Data are expressed as the mean ± SD or number of subjects (%). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; EF: ejection fraction; LVEDD: left end diastolic diameter; CAD: coronary artery disease; PTCA: percutaneous transluminal coronary angioplasty; CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; ARBs: angiotensin II receptor blockers.
Table 2: Changes in some hemodynamic variables in HFpEF controls and HFpEF patients who underwent ET-CR.

| Variables       | Ctr Baseline | After 4 weeks | P    | ET-CR Baseline | After 4 weeks | P    |
|-----------------|--------------|---------------|------|----------------|---------------|------|
| SBP (mmHg), mean ± SD | 119.3 ± 11.0 | 119.75 ± 10.6 | 0.163| 121.5 ± 11.0   | 120.26 ± 8.8  | 0.026|
| DBP (mmHg), mean ± SD | 71.0 ± 5.3  | 71.5 ± 5.2    | 0.163| 72.0 ± 5.9     | 71.8 ± 5.3    | 0.159|
| EF (%), mean ± SD   | 57.9 ± 3.8   | 57.6 ± 3.5    | 0.110| 56.2 ± 4.0     | 57.22 ± 3.19  | 0.001|
| LVEDD (mm)         | 52.95 ± 4.19 | 53.15 ± 4.23  | 0.428| 52.0 ± 4.35    | 51.86 ± 3.96  | 0.442|

SBP: systolic blood pressure; DBP: diastolic blood pressure; EF: ejection fraction; LVEDD: left end diastolic diameter.

30 seconds. A rapid centrifuge of the sample (to prevent the sediment suspension) at 16000 rpm was performed keeping the temperature below 4°C. One hundred seventy-five microliters of liquid upper phase was transferred into the glass vial and freeze-dried overnight.

After the derivatization, the extract was transferred in a 100 μL insert for the autosampler injection. This was centrifuged for 5 minutes at 16000 rpm keeping the temperature below 4°C before injecting. The sample (2 μL) was analyzed using a gas chromatography-mass spectrometry (GC-MS) system (GC-2010 Plus gas chromatography coupled to a 2010 Plus single quadrupole mass spectrometer; Shimadzu Corp., Kyoto, Japan). Chromatographic separation was achieved with a 30 m 0.25 mm CP-Sil 8 CB fused silica capillary GC column with 1.00 μm film thickness from Agilent (Agilent, J&W), with helium as the carrier gas.

βOHB was evaluated quantitatively by the use of external calibration. The analytical standard was purchased from Sigma-Aldrich (Milan, Italy). Five calibration standards were prepared, freeze-dried overnight to eliminate the solvent, and derivatized with the same procedure of the samples. GC-MS βOHB calibration curve showed an \( R^2 = 0.997 \), while replicated samples analysis showed a coefficient of variation (CV) < 10% and the analytical standard was analyzed in triplicate.

2.6. Oxidative Stress Markers. Total antioxidant capacity (Trolox Equivalent Antioxidant Capacity (TEAC)) and Oxidized Low-Density Lipoproteins (Ox-LDL) were measured in plasma samples isolated from the patients who underwent the ET-CR and the controls. The TEAC assay was performed according to the protocol already described in the authors’ previous study [28].

The levels of Ox-LDL were determined, by using a human Ox-LDL ELISA Kit (MyBiosource, Inc., USA) and 96 flat bottom transparent polystyrene plates (Thermo Fisher Scientific, USA), following the manufacturer’s instructions.

2.7. NAD⁺/NADH Ratio. NAD⁺/NADH ratio was quantified using the EnzyCromTM NAD⁺/NADH Assay Kit with a detection limit of 0.05 microM and linearity up to 10 microM (BioAssay Systems, Hayward, CA) and 96 flat bottom transparent polystyrene plates (Thermo Fisher Scientific, USA), following the manufacturer’s instructions. The optical density was read at 565 nm at time zero (OD0) and, after incubation (15 min), at room temperature (OD15). OD values were used to determine the NAD⁺/NADH concentration of each sample from a standard curve. All data are expressed as the mean ± SD of three independent experiments.

2.8. Statistical Analysis. Continuous variables are expressed as the mean ± standard deviation compared with paired or unpaired Student’s t-test (normally distributed variables), or as median ± interquartile range value compared with the Mann-Whitney U test (not normally distributed). Normality of data distribution was evaluated using the Kolmogorov-Smirnov test. Nonnormally distributed continuous variables were converted to their natural log functions. Categorical variables are expressed as a proportion and compared with the \( \chi^2 \) test.

Correlation between variables were assessed by linear regression analysis, and variables, which demonstrated statistical significance in a univariate model, were then included in a multivariate analysis. All data were analyzed using SPSS version 23.0 (SPSS, Inc., Chicago, Illinois, USA). Statistical significance was accepted at \( p < 0.05 \).

3. Results

The study population consisted of 70 male subjects (mean age 69.5 ± 4.27 years) affected by HFpEF. All patients completed the study. At baseline, no differences in medical therapy were found between the groups, and no therapeutic changes occurred during the study period (Table 1).

Table 1 shows the main demographic, hemodynamic, and chemical characteristics of the group who underwent a 4-week ET-CR program and the control group. Changes in some hemodynamic variables after 4 weeks are reported in Table 2. The ET-CR was able to induce a significant reduction in systolic blood pressure and an increase in ejection fraction. No changes were observed in the controls (Table 2).

Table 3 and Figure 1 show the changes in Sirt1 activity, βOHB, and oxidant and antioxidant parameters, at baseline and after 4 weeks. No differences were found between the groups at baseline, while significant differences were found between groups and intragroup (see above). The ET-CR induced a significant increase in Sirt1 activity, βOHB, and antioxidant capacity measured by TEAC assay, as shown by the raised levels of such parameters in the ET-CR group but not in the controls (Table 3 and Figures 1(a), 1(b), and 1(d)) and decreased levels of Ox-LDL in the ET-CR group but not in the controls (Figure 1(c)).

Moreover, the ET-CR was effective in inducing a significant increase in NAD⁺ and NAD⁺/NADH ratio and a
Table 3: Changes in oxidant/antioxidant parameters in HFpEF controls and HFpEF patients who underwent ET-CR.

| Variables                  | Ctr Baseline | After 4 weeks | P   | ET-CR Baseline | After 4 weeks | P       |
|----------------------------|--------------|---------------|-----|----------------|---------------|---------|
| SIRT1 activity (AU)        | 1941.80 ± 149.35 | 1942.16 ± 149.67 | 0.560 | 1953.14 ± 125.06 | 2082.44 ± 108.68 * | <0.0001 |
| βOHB (μmol/L)              | 47.96 ± 4.84 | 49.35 ± 5.21 | 0.280 | 48.76 ± 3.27 | 61.58 ± 6.91 * | <0.0001 |
| Ox-LDL (pg/mL)             | 3227.62 ± 281.13 | 3255.33 ± 388.57 | 0.492 | 3286.49 ± 527.08 | 2380.47 ± 608.30 * | <0.0001 |
| TEAC (mmol Trolox Equiv/L) | 0.295 ± 0.084 | 0.286 ± 0.722 | 0.075 | 0.290 ± 0.723 | 0.425 ± 0.061 * | <0.0001 |
| NAD⁺                      | 19.74 ± 2.03 | 18.41 ± 2.49 | 0.136 | 19.50 ± 1.48 | 21.64 ± 1.27 * | <0.0001 |
| NADH                      | 12.26 ± 1.43 | 13.25 ± 1.67 | 0.090 | 12.16 ± 0.97 | 11.15 ± 1.09 * | <0.001 |
| NAD⁺/NADH                 | 1.64 ± 0.32 | 1.44 ± 0.40 | 0.115 | 1.62 ± 0.24 | 1.96 ± 0.28 * | <0.0001 |

ET-CR: exercise training-based cardiac rehabilitation; βOHB: β-hydroxybutyrate; Ox-LDL: Oxidized Low-Density Lipoprotein. *CR vs. Ctr after 4 weeks, p < 0.0001.

Figure 1: Changes in control and ET-CR groups of Sirt1 activity, β-hydroxybutyrate, Ox-LDL levels, and TEAC from baseline to 4 weeks after the study start. The ET-CR was able to induce a significant increase in Sirt1 activity (a) and β-hydroxybutyrate (βOHB) (b) (both, p < 0.0001); a reduction in Ox-LDL (c) (p < 0.001) and increased levels of antioxidant response measured by TEAC assay (d) (p < 0.0001), as showed by the difference between the levels after 4 weeks minus the levels at baseline.

decrease in NADH (all p < 0.0001, Table 3 and Figures 2(a), 2(c), and 2(d)), while no changes were found in the controls. All these findings were confirmed when all the parameters were expressed as differences between levels after 4 weeks minus baseline levels (delta, Figures 1–3). Notably, the
increasing delta levels of NAD$^+$ and NAD$^+$/NADH ratio were associated with increasing levels of delta Sirt1 activity (Figures 2(a)–2(c)), as expected by the requirement of NAD$^+$ for Sirt1 activity.

By a multivariate linear regression analysis, introducing the delta TEAC as a dependent variable, we found that the best predictors of the changes in antioxidant levels were represented by the delta Sirt1 activity ($p < 0.0001$, $r^2 = 0.845$; $\beta = 0.000$; 95% CI 0.000–0.001; Figure 3(a)) and the ET-CR group ($p < 0.0001$, $\beta = 0.061$; 95% CI 0.045–0.076) followed by the delta $\beta$OHB levels ($p = 0.032$, $r^2 = 0.840$; $\beta = 0.002$; 95% CI 0.000–0.004; Figure 3(b)). Moreover, introducing the delta Ox-LDL as dependent variable, we found that the best predictors of the oxidant levels changes were represented by the delta Sirt1 activity ($p < 0.0001$, $r^2 = 0.812$; $\beta = -5.639$; 95% CI -6.839 to -4.438; Figure 3(c)) and the ET-CR group ($p < 0.0001$, $\beta = -510.5$; 95% CI -614.3 to -406.7). In particular, higher changes in TEAC and Ox-LDL were associated with higher changes in SIRT1 activity in a direct ($r^2 = 0.845$, Figure 3(a)) and inverse relationship ($r^2 = 0.812$, Figure 3(c)), respectively.

Finally, introducing in a multivariate linear regression analysis the delta NAD$^+$ as a dependent variable, we found that the best predictors were the delta Sirt1 activity ($p < 0.0001$, $r^2 = 0.915$; $\beta = 0.051$; 95% CI 0.037–0.065; Figure 3(d)), followed by the ET-CR group ($p = 0.004$, $\beta = 2.71$; 95% CI 0.920–4.494).

A strong direct association was found between the delta Sirt1 activity and the delta of NAD$^+$ levels ($r^2 = 0.915$, Figure 3(d)) and between the delta of $\beta$OHB levels and the delta of Sirt1 activity ($r^2 = 0.901$, Figure 3(e)).

4. Discussion

In the present study, we have demonstrated that a well-structured 4-week ET-CR program was able to increase the levels of Sirt1 activity and $\beta$-hydroxybutyrate, and these
Figure 3: Linear regression correlation among delta Sirt1 activity and delta oxidants and antioxidants. (a) Linear regression correlation between TEAC and delta Sirt1 activity. (b) Linear regression correlation between delta TEAC and delta βOHB levels. (c) Linear regression correlation between delta Ox-LDL and delta Sirt1 activity. (d) Linear regression correlation between delta NAD+ and delta Sirt1 activity. (e) Linear regression correlation between delta βOHB levels and delta Sirt1 activity.
findings were associated with an improvement of TEAC and a reduction of Ox-LDL.

To treat and especially manage the patients with HFpEF can be very challenging. This is mostly caused by a significant lack of knowledge in this field. For this reason, there is now high interest to elucidate the pathophysiology of the different HF phenotypes.

From a molecular point of view, the ET-CR might represent not only a valuable complementary therapeutic approach but also a study model to expose the molecular actors involved in HFpEF.

Previously, we demonstrated that Sirt1 was able to mediate the ET-CR effects at a molecular level inducing activation of its target catalase [19].

Several studies have demonstrated that both Sirt1 and βOHB are involved in the antioxidant cellular response. In particular, increased circulating levels of βOHB were linked to a reduction in oxidative stress [29], increased AMPK activity [30], and autophagy [31].

Moreover, βOHB was found to be an endogenous inhibitor of class I and IIa histone deacteylases (HDACs) [32] but not of the sirtuins (class III HDACs) representing a structurally distinct group of NAD-dependent deacteylases, in which βOHB is not known to directly regulate [33].

βOHB seems to work as a mimetic of caloric restriction that is the most known natural activator of some sirtuins [21]. Edwards et al. [34] have demonstrated that a βOHB administration in C. elegans delayed glucose toxicity and extended the worm’s lifespan in a Sir2- (the homolog of the human Sirt1) dependent manner. Therefore, these authors have proposed βOHB as a valuable treatment against aging-associated disorders [34].

Similar to the caloric restriction, the exercise training (ET) is recognized as a helpful tool against cardiovascular diseases. Indeed, ET is widely recommended in HF for its beneficial effects on the exercise tolerance [35].

Noteworthy, both caloric restriction and ET are associated with a significant increase of ketone bodies, such as βOHB [36–38].

Although the metabolic profiles differ in dependence on the timing and duration of physical activity, both short-term and long-term studies have sought to characterize the biochemical response to exercise [36]. Interestingly, Matoulek et al. showed that βOHB increased after exercise in patients who underwent a three-month fitness program [39].

Moreover, an acute bout of aerobic exercise increases class IIa HDAC phosphorylation and subsequent nuclear exclusion, thus inhibiting HDAC-mediated repression of specific exercise-responsive genes such as GLUT4 and PGC-1α [40, 41]. This suggests that compounds such as βOHB could be used to mimic or enhance adaptations to a physical exercise [36].

In our study, an ET-CR program was able to induce, in patients affected by HFpEF, an increase of both Sirt1 and βOHB, in association to a better antioxidant activity, as showed by higher levels of TEAC and NAD+.

Notably, it has been proposed that the relative sparing of cytoplasmic NAD levels with the utilization of βOHB, rather than glucose, can alter the activity of NAD-dependent enzymes such as sirtuins [42]. Recent studies observed an increase in the mitochondrial β-hydroxybutyrate dehydrogenase (BDH1), which coincided with elevated plasma levels of βOHB in both rodent and human models of heart failure [43, 44]. Increased amount of βOHB oxidation in isolated perfused hearts was also found [43]. These studies suggested that the increase of ketone body metabolism could represent an additional strategy leading to a metabolic remodeling in the failing heart. However, whether this is an adaptive or maladaptive response remains uncertain [45]. In this context, to better characterize the ET-CR effects from the metabolic point of view can represent an important step to improve the HFpEF management.

4.1. Limitations. A possible limitation of this study is the lack of cell sorting useful to identify what cells compose the PBMCs that could be mainly involved in the observed molecular modifications. However, Sirt1 is a ubiquitous molecule and several studies have shown changes in Sirt1 activity in PBMCs without a distinction of the PBMC cell types [28, 46].

Another limitation could be the lack of women in the study population. We did recruit only three women and then decided to exclude them because of the small number. This is in line with the fact that women are less inclined to take part in exercise training-based cardiac rehabilitation programs [47, 48]. Therefore, further studies are necessary to better clarify the molecular effects of ET-CR also in female patients.

5. Conclusions

The ability of exercise training to regulate metabolic and oxidative stress response can explain why ET-CR can be considered a sort of pharmacological tool in CVD management. In particular, ET-CR is a helpful medical practice in which several molecular factors mutually influence each other. The exercise training included in CR programs acts as a nonpharmacological inducer of antioxidant response. The HFpEF represents a peculiar phenotype of HF whose pathophysiological aspects have yet to be clarified.

Further studies should be addressed to evaluate the role of ET-CR in influencing the evolution of HFpEF considering the molecular changes induced by this tool to better clarify the mechanism and the pathway involved in the genesis and progression of the disease.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors have no conflicts of interest to report.

Authors’ Contributions

All authors read and met the Oxidative Medicine and Cellular Longevity criteria for authorship. Valeria Conti, Graziama Corbi, and Amelia Filippelli conceived and designed the experiments. Jacopo Troisi, Angelo Colucci, Valentina
Manzo, and Albino Carrizzo performed the experiments. Carmine Vecchione, Maria Consigilia Calabrese, and Paola Di Pietro contributed with acquisition of clinical data and human samples. Graziamaria Corbi and Valeria Conti performed the analysis and interpretation of the data and wrote the first draft of the paper. Nicola Ferrara and Amelia Filippelli critically revised the paper. All authors read and approved the final paper. Graziamaria Corbi and Valeria Conti contributed equally to this work.

Acknowledgments

We thank Jan Festa who revised and edited the English language of the manuscript. This work was supported by the Department of Medicine and Health Sciences of the University of Molise (R-DIPA_20112013300118CORBI-GR to G.C.) and the Department of Medicine, Surgery and Dentistry of the University of Salerno (ORSA153180).

References

[1] D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Heart disease and stroke statistics—2016 Update,” Circulation, vol. 133, no. 4, pp. e38–e360, 2016.
[2] M. A. H. Witman, J. McDaniel, A. S. Fjeldstad et al., “A differing role of oxidative stress in the regulation of central and peripheral hemodynamics during exercise in heart failure,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, pp. H1237–H1244, 2012.
[3] T. Ide, H. Tsutsui, S. Kinugawa et al., “Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium,” Circulation Research, vol. 86, no. 2, pp. 152–157, 2000.
[4] G. Corbi, V. Conti, K. Komici et al., “Phenolic plant extracts induce Sirt1 activity and increase antioxidant levels in the rabbit’s heart and liver,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 2731289, 10 pages, 2018.
[5] N. Anilkumar, A. Sirker, and A. M. Shah, “Redox sensitive signaling pathways in cardiac remodeling, hypertrophy and failure,” Frontiers in Bioscience, no. 14, pp. 3168–3187, 2009.
[6] V. Conti, G. Corbi, V. Simeon et al., “Aging-related changes in oxidative stress response of human endothelial cells,” Aging Clinical and Experimental Research, vol. 27, no. 4, pp. 547–553, 2015.
[7] D. B. Sawyer, “Oxidative stress in heart failure: what are we missing?,” The American Journal of the Medical Sciences, vol. 342, no. 2, pp. 120–124, 2011.
[8] F. J. Giordano, “Oxygen, oxidative stress, hypoxia, and heart failure,” The Journal of Clinical Investigation, vol. 115, no. 3, pp. 500–508, 2005.
[9] C. W. Yancy, M. Jessup, B. Bozkurt et al., “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America,” Journal of Cardiac Failure, vol. 23, no. 8, pp. 628–651, 2017.
[10] G. Corbi, G. Gambassi, G. Pagano et al., “Impact of an innovative educational strategy on medication appropriate use and length of stay in elderly patients,” Medicine, vol. 94, no. 24, p. e918, 2015.
[11] D. W. Kitzman, B. Upadhyya, and S. Vasu, “What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction,” Circulation, vol. 131, no. 6, pp. 522–524, 2015.
[12] K. Sharma and D. A. Kass, “Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies,” Circulation Research, vol. 115, no. 1, pp. 79–96, 2014.
[13] W. G. Hunter, J. P. Kelly, R. W. McGarrah III et al., “Metabolic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure,” Journal of the American Heart Association, vol. 5, no. 8, 2016.
[14] A. Pandey, A. Parashar, D. J. Kumbhani et al., “Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials,” Circulation: Heart Failure, vol. 8, no. 1, pp. 33–40, 2015.
[15] G. Corbi, V. Conti, G. Russomanno et al., “Is physical activity able to modify oxidative damage in cardiovascular aging?,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 728547, 6 pages, 2012.
[16] P. Meyer, M. Gayda, M. Juneau, and A. Nigam, “High-intensity aerobic interval exercise in chronic heart failure,” Current Heart Failure Reports, vol. 10, no. 2, pp. 130–138, 2013.
[17] V. Conti, M. Forte, G. Corbi et al., “Sirtuins: possible clinical implications in cardio and cerebrovascular diseases,” Current Drug Targets, vol. 18, no. 4, pp. 473–484, 2017.
[18] C.-H. Peng, Y.-L. Chang, C.-L. Kao et al., “SirT1—a sensor for monitoring self-renewal and aging process in retinal stem cells,” Sensors, vol. 10, no. 6, pp. 6172–6194, 2010.
[19] G. Russomanno, G. Corbi, V. Manzo et al., “The anti-ageing molecule sirt1 mediates beneficial effects of cardiac rehabilitation,” Immunity & Ageing, vol. 14, p. 7, 2017.
[20] M. Nagao, R. Toh, Y. Irino et al., “β-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes,” Biochemical and Biophysical Research Communications, vol. 475, no. 4, pp. 322–328, 2016.
[21] R. L. Veech, P. C. Bradshaw, K. Clarke, W. Curtis, R. Pawlosky, and M. T. King, “Ketone bodies mimic the life span extending properties of caloric restriction,” IUBMB Life, vol. 69, no. 5, pp. 305–314, 2017.
[22] V. Gallo, M. Egger, V. McCormack et al., “Strengthening the reporting of observational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement,” PLoS Medicine, vol. 8, no. 10, article e1001117, 2011.
[23] J. J. V. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 33, no. 14, pp. 1787–1847, 2012.
[24] C. W. Yancy, M. Jessup, B. Bozkurt et al., “2013 ACCF/AHA guideline for the management of heart failure: Executive Summary,” Circulation, vol. 128, no. 16, pp. 1810–1852, 2013.
[25] M. F. Piepoli, U. Corrà, W. Benzer et al., “Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation,” European Journal of
Cardiovascular Prevention and Rehabilitation, vol. 17, no. 1, pp. 1–17, 2010.

[26] K. Wasserman, J. E. Hansen, D. Y. Sue, W. W. Stringer, and B. J. Whipp, Principles of Exercise Testing and Interpretation, Lippincott Williams & Wilkins, Philadelphia, 5th edition, 2012.

[27] J. Troisi, L. Sarno, A. Landolfi et al., “Metabolomic signature of endometrial cancer,” Journal of Proteome Research, vol. 17, no. 2, pp. 804–812, 2018.

[28] V. Conti, G. Corbi, V. Manzo et al., “SIRT1 activity in peripheral blood mononuclear cells correlates with altered lung function in patients with chronic obstructive pulmonary disease,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 9391261, 8 pages, 2018.

[29] T. Shimazu, M. D. Hirschey, J. Newman et al., “Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor,” Science, vol. 339, no. 6116, pp. 211–214, 2013.

[30] T. Laeger, R. Pöhland, C. C. Metges, and B. Kuhla, “The ketone body β-hydroxybutyric acid influences agouti-related peptide expression via AMP-activated protein kinase in hypothalamic GT1-7 cells,” The Journal of Endocrinology, vol. 213, no. 2, pp. 193–203, 2012.

[31] P. F. Finn and J. F. Dice, “Ketone bodies stimulate chaperone-mediated autophagy,” Journal of Biological Chemistry, vol. 280, no. 27, pp. 25864–25870, 2005.

[32] I. V. Gregorietti, Y. M. Lee, and H. V. Goodson, “Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis,” Journal of Molecular Biology, vol. 338, no. 1, pp. 17–31, 2004.

[33] X. J. Yang and E. Seto, “The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 206–218, 2008.

[34] C. Edwards, J. Canfield, N. Copes, M. Rehan, D. Lipps, and P. C. Bradshaw, “D-beta-hydroxybutyrate extends lifespan in C. elegans,” Aging, vol. 6, no. 8, pp. 621–644, 2014.

[35] F. Edelmann, G. Gelbrich, H. D. Düngen et al., “Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study,” Journal of the American College of Cardiology, vol. 58, no. 17, pp. 1780–1791, 2011.

[36] M. Evans, K. E. Cogan, and B. Egan, “Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation,” The Journal of Physiology, vol. 595, no. 9, pp. 2857–2871, 2017.

[37] J. C. Newman and E. Verdin, “β-Hydroxybutyrate: a signaling metabolite,” Annual Review of Nutrition, vol. 37, no. 1, pp. 51–76, 2017.

[38] E. F. Sutton, R. Beyl, K. S. Early, W. T. Cefalu, E. Ravussin, and C. M. Peterson, “Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes,” Cell Metabolism, vol. 27, no. 6, pp. 1212–1221.e3, 2018.

[39] M. Matoulek, S. Svobodova, R. Vetroskova, Z. Stranska, and S. Svacina, “Post-exercise changes of beta hydroxybutyrate as a predictor of weight changes,” Physiological Research, vol. 63, Supplement 2, pp. S321–S325, 2014.

[40] S. L. McGee, E. Fairlie, A. P. Garnham, and M. Hargreaves, “Exercise-induced histone modifications in human skeletal muscle,” The Journal of Physiology, vol. 587, Part 24, pp. 5951–5958, 2009.

[41] B. Egan, B. P. Carson, P. M. Garcia-Roves et al., “Exercise intensity-dependent regulation of peroxisome proliferator-activated receptor coactivator-1 mRNA abundance is associated with differential activation of upstream signalling kinases in human skeletal muscle,” The Journal of Physiology, vol. 588, no. 10, pp. 1779–1790, 2010.

[42] J. C. Newman and E. Verdin, “β-hydroxybutyrate: much more than a metabolite,” Diabetes Research and Clinical Practice, vol. 106, no. 2, pp. 173–181, 2014.

[43] G. Aubert, O. J. Martin, J. L. Horton et al., “The failing heart relies on ketone bodies as a fuel,” Circulation, vol. 133, no. 8, pp. 698–705, 2016.

[44] K. C. Bedi Jr., N. W. Snyder, J. Brandimarto et al., “Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure,” Circulation, vol. 133, no. 8, pp. 706–716, 2016.

[45] S. C. Kolwicz Jr., S. Airhart, and R. Tian, “Ketones step to the plate: a game changer for metabolic remodeling in heart failure?,” Circulation, vol. 133, no. 8, pp. 689–691, 2016.

[46] D. Wendling, W. Abbas, M. Godfrin-Valnet et al., “Dysregulated serum IL-23 and SIRT1 activity in peripheral blood mononuclear cells of patients with rheumatoid arthritis,” PLoS One, vol. 10, no. 3, article e0119981, 2015.

[47] P. O’Farrell, J. Murray, P. Huston, C. LeGrand, and K. Adamo, “Sex differences in cardiac rehabilitation,” The Canadian Journal of Cardiology, vol. 16, no. 3, pp. 319–325, 2000.

[48] S. L. Grace, C. Racco, C. Chessex, T. Rivera, and P. Oh, “A narrative review on women and cardiac rehabilitation: program adherence and preferences for alternative models of care,” Maturitas, vol. 67, no. 3, pp. 203–208, 2010.